Clinics in Dermatology
Volume 27, Issue 6 , Pages 588-593 , November 2009

What sentinel node biopsy in patients with melanoma (or patients whose doctors worry that they could have melanoma) might and might not do

References 

  1. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–2147
  2. Shidham VB, Qi DY, Acker S, et al. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. Am J Surg Pathol. 2001;25:1039–1046
  3. Biddle DA, Evans HL, Kemp BL, et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol. 2003;27:673–681
  4. Rodriguez HA, Ackerman LV. Cellular blue nevus. Clinicopathologic study of forty-five cases. Cancer. 1968;21:393–405
  5. Epstein JI, Erlandson RA, Rosen PP. Nodal blue nevi. A study of three cases. Am J Surg Pathol. 1984;8:907–915
  6. Von Albertini M. Sur un cas de neuro-naevus avec metastase ganglionnaiere de meme caractere. Bull Soc Franc Derm Syph. 1935;42:1273
  7. Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol. 2007;14:1934–1942
  8. Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group: sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  9. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol. 2008;5:18–23
  10. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol. 2005;29:1145–1151
  11. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346
  12. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–2051

PII: S0738-081X(08)00193-4

doi: 10.1016/j.clindermatol.2008.09.016

Clinics in Dermatology
Volume 27, Issue 6 , Pages 588-593 , November 2009

Article Tools

* Image Usage & Resolution